Barclays upgrades Victoria's Secret to Overweight rating, citing potential top-line acceleration and operating margin ...
In this episode of The Big Question, Barclays Europe CEO, Francesco Ceccato, joins Euronews’ business editor, Angela Barnes, ...
Barclays Plc is preparing for a wave of dealmaking on both sides of the Atlantic as newly installed President Donald Trump ...
Barclays has announced the closure of its fintech accelerator program, Rise, by mid-2025, leaving the New York fintech ...
The average age of first-time buyer in the UK rose to almost 34 last year, according to Barclays’ proprietary data, as people ...
Barclays analyst Brendan Lynch has believed that data center multiples were vulnerable to any shift in narrative around artificial intelligence ...
Sarah Coles, head of Personal Finance at investment platform Hargreaves Lansdown, said: “If you were to pay in £300 a month ...
If Banco Santander’s Ana Botín wants to sell her British retail business, there’s an obvious buyer: Barclays boss C. S.
Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $28.00.
UK banking giants are paying an average of just 1.42 percent on their easy access accounts - far below the market average of ...
Talen Energy Corp. (TLN) stock received a price target bump from analysts at Barclays as part of the company’s fourth-quarter ...